Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 212 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Drowsiness Clear all
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

NCT07625280
View directory record Official record
Conditions
Narcolepsy, Idiopathic Hypersomnia
Interventions
Xywav, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Irvine, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 4:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Predictors of Post-COVID-19 Clinical and Cognitive Consequences

NCT06291870
View directory record Official record
Conditions
Post Acute Sequelae of SARS CoV 2 Infection, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 23, 2026, 4:13 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Nextsense Brain-sensing Buds Study

NCT06602960
View directory record Official record
Conditions
Sleep, Sleep Quality, Sleepiness, Daytime, Technology
Interventions
Accurate Sleep Data Feedback, Inflated Sleep Data Feedback, Deflated Sleep Data Feedback, Accurate Sleep Data Feedback + Sleep-related Educational Information
Behavioral
Lead sponsor
NextSense, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 23, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional

Bright Light Therapy for OSA

NCT05917119
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
BLT, s-BLT
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 23, 2026, 4:13 PM EDT
Completed No phase listed Observational

Can Sleep Apnea Screening Questionnaire Predict Adverse Events in Endoscopic Studies

NCT03436381
View directory record Official record
Conditions
Sleep Apnea, Adverse Event
Interventions
Questionaire
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
350 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 23, 2026, 4:13 PM EDT
Recruiting Phase 3 Interventional

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

NCT06568367
View directory record Official record
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Auburn, Alabama • Cullman, Alabama • Chandler, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"

NCT02348632
View directory record Official record
Conditions
Narcolepsy, Obstructive Sleep Apnea
Interventions
JZP-110
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
63
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Outcomes for Patients With SDB and Insufficient Sleep

NCT04279834
View directory record Official record
Conditions
Sleep Apnea, Insufficient Sleep Syndrome, Sleep, Hypertension
Interventions
PAP Treatment, Sleep Education I
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Results available

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

NCT04789174
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Santa Ana, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 4:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleepiness and Brain Function: The Effect of Armodafinil in Shift Work Sleep Disorder

NCT00688142
View directory record Official record
Conditions
Shift Work Sleep Disorder
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2010 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management

NCT00801892
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Diabetes Mellitus, Type 2
Interventions
Continuous Positive Airway Pressure (CPAP), Sham- Continuous Positive Airway Pressure (Sham-CPAP)
Device
Lead sponsor
Eileen R. Chasens
Other
Eligibility
40 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)

NCT06525077
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
FT218, Placebo
Drug · Other
Lead sponsor
Avadel
Industry
Eligibility
18 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Boulder, Colorado • Winter Park, Florida • Stockbridge, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional

Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

NCT02703207
View directory record Official record
Conditions
Obstructive Sleep Apnea, OSA COPD Overlap Syndrome
Interventions
Positive airway pressure, NIPPV and /or oxygen
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 89 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

NCT01124851
View directory record Official record
Conditions
Sleep Disorder
Interventions
ABT-652, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Phoenix, Arizona • Glendale, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance

NCT00711516
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Burlingame, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 23, 2026, 4:13 PM EDT
Terminated Phase 1 Interventional Results available

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

NCT06179407
View directory record Official record
Conditions
Narcolepsy
Interventions
MK-6552, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Colorado Springs, Colorado • Brandon, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 23, 2026, 4:13 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Aprepitant to Mitigate Opioids' Cognitive Side Effects

NCT02226601
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Effects of Hemodialysis on the Sleep/Wake Cycle

NCT00460863
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
using cool versus warm dialysate during hemodialysis
Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 23, 2026, 4:13 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00893789
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil, Placebo
Drug · Other
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
68
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 23, 2026, 4:13 PM EDT
Recruiting Phase 2 Interventional

Extended-release Sodium Oxybate in Children

NCT06809803
View directory record Official record
Conditions
Narcolepsy Type 1 (NT 1)
Interventions
Extended-release sodium oxybate, Non-extended-release oxybates
Drug
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Treating Sleep Apnea on Cognition in Patients With Dementia

NCT00477828
View directory record Official record
Conditions
Dementia, Sleep Apnea
Interventions
Continuous positive airway pressure
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2007 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

NCT03624920
View directory record Official record
Conditions
Parkinson Disease
Interventions
THN102 Dosage A, THN102 Dosage B, THN102 Dosage C
Drug
Lead sponsor
Theranexus
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 23, 2026, 4:13 PM EDT
Recruiting No phase listed Observational

SUNOSI® (Solriamfetol) Pregnancy Registry

NCT06413420
View directory record Official record
Conditions
Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
Interventions
Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants, No treatment
Drug · Other
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
Female only
Enrollment
1,731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
2
States / cities
Morrisville, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Lorazepam on Cognition in APOE e4 Carriers

NCT00586430
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
lorazepam, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 23, 2026, 4:13 PM EDT